{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T23:15:35Z","timestamp":1787786135735,"version":"build-2784847793"},"reference-count":87,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,11,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Mrs. A. is a 73-year-old woman who has developed increasing fatigue and lower back pain over the past year. The pain limits her exercise tolerance such that she can now walk only 1 block. She is a retired schoolteacher who does volunteer efforts in her community but has limited her activities due to fatigue. Karnofsky performance status is 70%. She has a history of chronic hypertension treated with a diuretic, adult-onset diabetes mellitus treated with metformin, and hypothyroidism treated with levothyroxine. Initial evaluation reveals anemia, renal dysfunction, an elevated total protein, and an L2 compression fracture on lumbosacral radiographs. Results of initial and subsequent evaluation are shown below, and she is referred to a hematologist for further evaluation, which revealed the following: calcium 9.0 mg\/dL, creatinine 3.2 mg\/dL with estimated creatinine clearance using the Modification of Diet in Renal Disease equation of 15 mL\/min, hemoglobin 9.6 g\/dL, total protein 11 g\/dL, albumin 3.2 g\/dL, immunoglobulin A (IgA) \u03bb M protein 6.8 g\/dL, total IgA 7.2 g\/dL, IgG 0.4g\/dL, IgM 0.03 g\/dL, free \u03ba &lt;0.01 mg\/L, free \u03bb 1000 mg\/L, serum free light chain ratio &lt;0.01, \u03b2-2\u2013microglobulin 4.2, viscosity 3.0, lactate dehydrogenase 200 U\/L, urine protein electrophoresis: 125 mg\/dL with 30% M protein, and urine immunofixation: \u03bb light chain. Skeletal bone survey showed lytic lesions in femurs and humeri and diffusely in ribs bilaterally as well as compression fractures at T4, T6, and L2. Bone marrow biopsy revealed \u03bb-restricted plasma cells comprising 50% of the bone marrow core. Fluorescence in situ hybridization testing on marrow showed that del 17p was present in 80% of the plasma cells. Mrs. A. is informed of the diagnosis of multiple myeloma and the need for therapy. She requests consultation with 2 of the leading world experts. However, she wants to be treated near her home and does not want treatment on a clinical trial.<\/jats:p>","DOI":"10.1182\/asheducation-2018.1.88","type":"journal-article","created":{"date-parts":[[2019,4,16]],"date-time":"2019-04-16T22:13:59Z","timestamp":1555452839000},"page":"88-96","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":20,"title":["Approach to the treatment of the older, unfit patient with myeloma from diagnosis to relapse: perspectives of a US hematologist and a geriatric hematologist"],"prefix":"10.1182","volume":"2018","author":[{"given":"Tanya M.","family":"Wildes","sequence":"first","affiliation":[{"name":"Division of Medical Oncology, Washington University School of Medicine, St. Louis, MO; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth C.","family":"Anderson","sequence":"additional","affiliation":[{"name":"Jerome Lipper Multiple Myeloma Center, LeBow Institute for Myeloma Therapeutics, Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"26","key":"2019111522000051200_B1","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised international staging system for multiple myeloma: a report from International Myeloma Working Group","volume":"33","author":"Palumbo","year":"2015","journal-title":"J Clin Oncol"},{"issue":"2","key":"2019111522000051200_B2","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1182\/blood-2014-10-609461","article-title":"Future distribution of multiple myeloma in the United States by sex, age, and race\/ethnicity","volume":"125","author":"Rosenberg","year":"2015","journal-title":"Blood"},{"issue":"4","key":"2019111522000051200_B3","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1200\/JCO.1998.16.4.1582","article-title":"Comorbidity and functional status are independent in older cancer patients","volume":"16","author":"Extermann","year":"1998","journal-title":"J Clin Oncol"},{"issue":"2","key":"2019111522000051200_B4","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1200\/JCO.2002.20.2.494","article-title":"Comprehensive geriatric assessment adds information to Eastern Cooperative Oncology Group performance status in elderly cancer patients: an Italian Group for Geriatric Oncology Study","volume":"20","author":"Repetto","year":"2002","journal-title":"J Clin Oncol"},{"issue":"3","key":"2019111522000051200_B5","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1093\/gerona\/59.3.M255","article-title":"Untangling the concepts of disability, frailty, and comorbidity: implications for improved targeting and care","volume":"59","author":"Fried","year":"2004","journal-title":"J Gerontol A Biol Sci Med Sci"},{"issue":"22","key":"2019111522000051200_B6","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1200\/JCO.2018.78.8687","article-title":"Practical assessment and management of vulnerabilities in older patients receiving chemotherapy: ASCO Guideline for Geriatric Oncology","volume":"36","author":"Mohile","year":"2018","journal-title":"J Clin Oncol"},{"issue":"13","key":"2019111522000051200_B7","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1182\/blood-2014-12-615187","article-title":"Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report","volume":"125","author":"Palumbo","year":"2015","journal-title":"Blood"},{"issue":"1","key":"2019111522000051200_B8","first-page":"309","article-title":"Comprehensive geriatric assessment and decision-making in older men with incurable but manageable (chronic) cancer","volume":"319","author":"Handforth","year":"2018","journal-title":"Support Care Cancer"},{"issue":"3","key":"2019111522000051200_B9","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/ejh.13009","article-title":"Falls in older adults with multiple myeloma","volume":"100","author":"Wildes","year":"2018","journal-title":"Eur J Haematol"},{"issue":"9","key":"2019111522000051200_B10","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.3324\/haematol.2016.148189","article-title":"Geriatric assessment in multiple myeloma patients: validation of the International Myeloma Working Group (IMWG) score and comparison with other common comorbidity scores","volume":"101","author":"Engelhardt","year":"2016","journal-title":"Haematologica"},{"issue":"2","key":"2019111522000051200_B11","first-page":"130","article-title":"Geriatric assessment to predict survival and risk of serious adverse events in elderly newly diagnosed multiple myeloma patients: a multicenter study in China","volume":"130","author":"Zhong","year":"2017","journal-title":"Chin Med J (Engl)"},{"issue":"3","key":"2019111522000051200_B12","doi-asserted-by":"crossref","first-page":"M146","DOI":"10.1093\/gerona\/56.3.M146","article-title":"Frailty in older adults: evidence for a phenotype","volume":"56","author":"Fried","year":"2001","journal-title":"J Gerontol A Biol Sci Med Sci"},{"issue":"5","key":"2019111522000051200_B13","doi-asserted-by":"crossref","first-page":"910","DOI":"10.3324\/haematol.2016.162693","article-title":"A concise revised Myeloma Comorbidity Index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients","volume":"102","author":"Engelhardt","year":"2017","journal-title":"Haematologica"},{"issue":"7","key":"2019111522000051200_B14","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1093\/gerona\/62.7.722","article-title":"Frailty in relation to the accumulation of deficits","volume":"62","author":"Rockwood","year":"2007","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"2019111522000051200_B15","article-title":"Development of a Medicare health outcomes survey deficit-accumulation frailty index and its application to older patients with newly diagnosed multiple myeloma [published online ahead of print 25 July 2018]","volume-title":"JCO Clin Cancer Inform","author":"Mian"},{"issue":"5","key":"2019111522000051200_B16","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.jgo.2015.03.003","article-title":"Development and psychometric validation of a brief comprehensive health status assessment scale in older patients with hematological malignancies: the GAH Scale","volume":"6","author":"Bonanad","year":"2015","journal-title":"J Geriatr Oncol"},{"issue":"3","key":"2019111522000051200_B17","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.jgo.2016.12.008","article-title":"Further psychometric validation of the GAH scale: responsiveness and effect size","volume":"8","author":"Cruz-Jentoft","year":"2017","journal-title":"J Geriatr Oncol"},{"issue":"24","key":"2019111522000051200_B18","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1182\/blood-2016-01-631200","article-title":"Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group","volume":"127","author":"Sonneveld","year":"2016","journal-title":"Blood"},{"key":"2019111522000051200_B19","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1038\/s41375-018-0142-9","article-title":"Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN)","volume":"32","author":"Larocca","year":"2018","journal-title":"Leukemia"},{"issue":"10068","key":"2019111522000051200_B20","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0140-6736(16)31594-X","article-title":"Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial","volume":"389","author":"Durie","year":"2017","journal-title":"Lancet"},{"issue":"6","key":"2019111522000051200_B21","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1038\/s41375-018-0098-9","article-title":"Front-line therapies for elderly patients with transplant-ineligible multiple myeloma and high-risk cytogenetics in the era of novel agents","volume":"32","author":"Avet-Loiseau","year":"2018","journal-title":"Leukemia"},{"issue":"9","key":"2019111522000051200_B22","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.clml.2017.06.013","article-title":"Analysis of common eligibility criteria of randomized controlled trials in newly diagnosed multiple myeloma patients and extrapolating outcomes","volume":"17","author":"Shah","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"9","key":"2019111522000051200_B23","doi-asserted-by":"crossref","first-page":"e363","DOI":"10.1016\/j.clml.2018.06.008","article-title":"Multiple myeloma patients ineligible for randomized controlled trials have poorer outcomes irrespective of treatment","volume":"18","author":"Malecek","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"33","key":"2019111522000051200_B24","doi-asserted-by":"crossref","first-page":"3921","DOI":"10.1200\/JCO.2014.58.7618","article-title":"Community-based phase IIIB trial of three UPFRONT bortezomib-based myeloma regimens","volume":"33","author":"Niesvizky","year":"2015","journal-title":"J Clin Oncol"},{"issue":"6","key":"2019111522000051200_B25","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1038\/leu.2016.36","article-title":"A phase 2 study of three low-dose intensity subcutaneous bortezomib regimens in elderly frail patients with untreated multiple myeloma","volume":"30","author":"Larocca","year":"2016","journal-title":"Leukemia"},{"issue":"6","key":"2019111522000051200_B26","doi-asserted-by":"crossref","first-page":"980","DOI":"10.3324\/haematol.2012.075051","article-title":"Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials","volume":"98","author":"Bringhen","year":"2013","journal-title":"Haematologica"},{"issue":"9779","key":"2019111522000051200_B27","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1016\/S0140-6736(11)60399-1","article-title":"Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial","volume":"377","author":"Seymour","year":"2011","journal-title":"Lancet"},{"issue":"11","key":"2019111522000051200_B28","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1056\/NEJMra1011442","article-title":"Multiple myeloma","volume":"364","author":"Palumbo","year":"2011","journal-title":"N Engl J Med"},{"issue":"24","key":"2019111522000051200_B29","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1200\/JCO.2014.55.1028","article-title":"Multiple myeloma in the older adult: better prospects, more challenges","volume":"32","author":"Wildes","year":"2014","journal-title":"J Clin Oncol"},{"issue":"17","key":"2019111522000051200_B30","doi-asserted-by":"crossref","first-page":"4519","DOI":"10.1182\/blood-2011-06-358812","article-title":"Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN)","volume":"118","author":"Palumbo","year":"2011","journal-title":"Blood"},{"issue":"5","key":"2019111522000051200_B31","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1097\/CCO.0000000000000395","article-title":"Elderly patients with multiple myeloma: towards a frailty approach?","volume":"29","author":"Zweegman","year":"2017","journal-title":"Curr Opin Oncol"},{"issue":"2","key":"2019111522000051200_B32","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/bjh.15261","article-title":"A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma","volume":"182","author":"O\u2019Donnell","year":"2018","journal-title":"Br J Haematol"},{"issue":"4","key":"2019111522000051200_B33","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/ajh.23933","article-title":"Effect of cumulative bortezomib dose on survival in multiple myeloma patients receiving bortezomib-melphalan-prednisone in the phase III VISTA study","volume":"90","author":"Mateos","year":"2015","journal-title":"Am J Hematol"},{"issue":"1","key":"2019111522000051200_B34","doi-asserted-by":"crossref","first-page":"11","DOI":"10.6004\/jnccn.2018.0002","article-title":"NCCN guidelines insights: multiple myeloma, version 3.2018","volume":"16","author":"Kumar","year":"2018","journal-title":"J Natl Compr Canc Netw"},{"issue":"6","key":"2019111522000051200_B35","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1056\/NEJMoa1714678","article-title":"Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma","volume":"378","author":"Mateos","year":"2018","journal-title":"N Engl J Med"},{"issue":"10","key":"2019111522000051200_B36","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa1402551","article-title":"Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma","volume":"371","author":"Benboubker","year":"2014","journal-title":"N Engl J Med"},{"issue":"1","key":"2019111522000051200_B37","doi-asserted-by":"crossref","first-page":"30","DOI":"10.5144\/1658-3876.2011.30","article-title":"Age at transplantation and outcome after autologous stem cell transplantation in elderly patients with multiple myeloma","volume":"4","author":"El Cheikh","year":"2011","journal-title":"Hematol Oncol Stem Cell Ther"},{"issue":"1","key":"2019111522000051200_B38","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2169\/internalmedicine.52.8390","article-title":"Evaluation of the feasibility and efficacy of autologous stem cell transplantation in elderly patients with multiple myeloma","volume":"52","author":"Muta","year":"2013","journal-title":"Intern Med"},{"issue":"5","key":"2019111522000051200_B39","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/leu.2013.313","article-title":"Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients","volume":"28","author":"Kumar","year":"2014","journal-title":"Leukemia"},{"issue":"8","key":"2019111522000051200_B40","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1038\/bmt.2015.106","article-title":"High-dose therapy and autologous stem cell transplant in older adults with multiple myeloma","volume":"50","author":"Wildes","year":"2015","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"2019111522000051200_B41","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(09)70284-0","article-title":"Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial","volume":"11","author":"Rajkumar","year":"2010","journal-title":"Lancet Oncol"},{"issue":"2","key":"2019111522000051200_B42","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/j.1365-2141.2004.05186.x","article-title":"Randomized comparison of dexamethasone combined with melphalan versus melphalan with prednisone in the treatment of elderly patients with multiple myeloma","volume":"127","author":"Hern\u00e1ndez","year":"2004","journal-title":"Br J Haematol"},{"issue":"7","key":"2019111522000051200_B43","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.clml.2016.04.012","article-title":"Cyclophosphamide and bortezomib with prednisone or dexamethasone for the treatment of relapsed and refractory multiple myeloma","volume":"16","author":"Reece","year":"2016","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"2","key":"2019111522000051200_B44","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.ijrobp.2009.07.1715","article-title":"Phase I trial of bortezomib and concurrent external beam radiation in patients with advanced solid malignancies","volume":"78","author":"Pugh","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"18","key":"2019111522000051200_B45","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1200\/JCO.2012.47.7901","article-title":"International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease","volume":"31","author":"Terpos","year":"2013","journal-title":"J Clin Oncol"},{"issue":"8","key":"2019111522000051200_B46","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1200\/JCO.2017.76.6402","article-title":"Role of bone-modifying agents in multiple myeloma: American Society of Clinical Oncology clinical practice guideline update","volume":"36","author":"Anderson","year":"2018","journal-title":"J Clin Oncol"},{"issue":"25","key":"2019111522000051200_B47","doi-asserted-by":"crossref","first-page":"2900","DOI":"10.1200\/JCO.2016.69.2517","article-title":"Depth of response in multiple myeloma: a pooled analysis of three PETHEMA\/GEM clinical trials","volume":"35","author":"Lahuerta","year":"2017","journal-title":"J Clin Oncol"},{"issue":"8","key":"2019111522000051200_B48","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"issue":"25","key":"2019111522000051200_B49","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1182\/blood-2016-03-705319","article-title":"Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients","volume":"127","author":"Paiva","year":"2016","journal-title":"Blood"},{"issue":"30","key":"2019111522000051200_B50","doi-asserted-by":"crossref","first-page":"3459","DOI":"10.1200\/JCO.2014.60.2466","article-title":"Continuous therapy versus fixed duration of therapy in patients with newly diagnosed multiple myeloma","volume":"33","author":"Palumbo","year":"2015","journal-title":"J Clin Oncol"},{"issue":"7","key":"2019111522000051200_B51","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1505654","article-title":"Elotuzumab therapy for relapsed or refractory multiple myeloma","volume":"373","author":"Lonial","year":"2015","journal-title":"N Engl J Med"},{"issue":"17","key":"2019111522000051200_B52","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMoa1516282","article-title":"Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"374","author":"Moreau","year":"2016","journal-title":"N Engl J Med"},{"issue":"8","key":"2019111522000051200_B53","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1056\/NEJMoa1606038","article-title":"Daratumumab, bortezomib, and dexamethasone for multiple myeloma","volume":"375","author":"Palumbo","year":"2016","journal-title":"N Engl J Med"},{"issue":"15 suppl","key":"2019111522000051200_B54","doi-asserted-by":"crossref","first-page":"8001","DOI":"10.1200\/JCO.2018.36.15_suppl.8001","article-title":"Pomalidomide (POM), bortezomib, and low-dose dexamethasone (PVd) vs bortezomib and low-dose dexamethasone (Vd) in lenalidomide (LEN)-exposed patients (pt) with relapsed or refractory mulitple myeloma (RRMM): phase 3 OPTIMISMM trial","volume":"36","author":"Richardson","year":"2018","journal-title":"J Clin Oncol"},{"issue":"6","key":"2019111522000051200_B55","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1111\/j.1365-2141.2008.07573.x","article-title":"Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline","volume":"144","author":"Richardson","year":"2009","journal-title":"Br J Haematol"},{"issue":"15 suppl","key":"2019111522000051200_B56","doi-asserted-by":"crossref","first-page":"10009","DOI":"10.1200\/JCO.2018.36.15_suppl.10009","article-title":"Patient-defined goals and preferences among older adults with cancer starting chemotherapy [abstract]","volume":"36","author":"Soto-Perez-de-Celis","year":"2018","journal-title":"J Clin Oncol"},{"issue":"8","key":"2019111522000051200_B57","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1182\/blood-2017-05-785246","article-title":"Daratumumab plus pomalidomide and dexamethasone in relapsed and\/or refractory multiple myeloma","volume":"130","author":"Chari","year":"2017","journal-title":"Blood"},{"issue":"4","key":"2019111522000051200_B58","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s40266-018-0539-1","article-title":"Novel treatments for multiple myeloma: what role do they have in older adults?","volume":"35","author":"Mian","year":"2018","journal-title":"Drugs Aging"},{"issue":"1","key":"2019111522000051200_B59","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1470-2045(15)00464-7","article-title":"Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study","volume":"17","author":"Dimopoulos","year":"2016","journal-title":"Lancet Oncol"},{"issue":"2","key":"2019111522000051200_B60","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa1411321","article-title":"Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma","volume":"372","author":"Stewart","year":"2015","journal-title":"N Engl J Med"},{"issue":"14","key":"2019111522000051200_B61","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","article-title":"Daratumumab, lenalidomide, and dexamethasone for multiple myeloma","volume":"375","author":"Dimopoulos","year":"2016","journal-title":"N Engl J Med"},{"issue":"11","key":"2019111522000051200_B62","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/S1470-2045(14)70440-1","article-title":"Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial","volume":"15","author":"San-Miguel","year":"2014","journal-title":"Lancet Oncol"},{"key":"2019111522000051200_B63","first-page":"14","article-title":"Elotuzumab plus pomalidomide\/dexamethasone (EPD) vs PD for treatment of relapsed\/refractory multiple myeloma (RRMM): results from the phase 2, randomized open-label ELOQUENT-3 study","volume-title":"Proceedings from the 23rd Congress of the European Hematology Association","author":"Dimopoulos"},{"key":"2019111522000051200_B64","first-page":"1","article-title":"Cardiotoxicity associated with carfilzomib: systematic review and meta-analysis","volume":"17","author":"Shah","year":"2018","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"2019111522000051200_B65","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1212\/01.wnl.0000267271.18475.fe","article-title":"Neuropathy in multiple myeloma treated with thalidomide: a prospective study","volume":"69","author":"Plasmati","year":"2007","journal-title":"Neurology"},{"key":"2019111522000051200_B66","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ctrv.2017.05.002","article-title":"Adherence to oral cancer therapy in older adults: the International Society of Geriatric Oncology (SIOG) taskforce recommendations","volume":"57","author":"Mislang","year":"2017","journal-title":"Cancer Treat Rev"},{"issue":"8","key":"2019111522000051200_B67","doi-asserted-by":"crossref","first-page":"e338","DOI":"10.1038\/bcj.2015.60","article-title":"Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomib","volume":"5","author":"Kumar","year":"2015","journal-title":"Blood Cancer J"},{"issue":"1 suppl","key":"2019111522000051200_B68","doi-asserted-by":"crossref","first-page":"e131","DOI":"10.1016\/j.clml.2017.03.237","article-title":"Phase 2 study of the all-oral combination of ixazomib plus cyclophosphamide and low-dose dexamethasone (ICd) in patients (Pts) with relapsed\/refractory multiple myeloma (RRMM)","volume":"17","author":"Kumar","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"3","key":"2019111522000051200_B69","doi-asserted-by":"crossref","first-page":"409","DOI":"10.2105\/AJPH.92.3.409","article-title":"When the caregiver needs care: the plight of vulnerable caregivers","volume":"92","author":"Navaie-Waliser","year":"2002","journal-title":"Am J Public Health"},{"issue":"10","key":"2019111522000051200_B70","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1634\/theoncologist.2014-0093","article-title":"Exclusion of older patients from ongoing clinical trials for hematological malignancies: an evaluation of the National Institutes of Health Clinical Trial Registry","volume":"19","author":"Hamaker","year":"2014","journal-title":"Oncologist"},{"issue":"33","key":"2019111522000051200_B71","doi-asserted-by":"crossref","first-page":"3737","DOI":"10.1200\/JCO.2017.73.7916","article-title":"Broadening eligibility criteria to make clinical trials more representative: American Society of Clinical Oncology and Friends of Cancer Research joint research statement","volume":"35","author":"Kim","year":"2017","journal-title":"J Clin Oncol"},{"issue":"25","key":"2019111522000051200_B72","doi-asserted-by":"crossref","first-page":"3457","DOI":"10.1200\/JCO.2011.34.7625","article-title":"Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study","volume":"29","author":"Hurria","year":"2011","journal-title":"J Clin Oncol"},{"issue":"20","key":"2019111522000051200_B73","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1200\/JCO.2015.65.4327","article-title":"Validation of a prediction tool for chemotherapy toxicity in older adults with cancer","volume":"34","author":"Hurria","year":"2016","journal-title":"J Clin Oncol"},{"issue":"13","key":"2019111522000051200_B74","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1002\/cncr.26646","article-title":"Predicting the risk of chemotherapy toxicity in older patients: the Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score","volume":"118","author":"Extermann","year":"2012","journal-title":"Cancer"},{"issue":"13","key":"2019111522000051200_B75","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1200\/JCO.2009.26.0638","article-title":"Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial","volume":"28","author":"Mateos","year":"2010","journal-title":"J Clin Oncol"},{"issue":"10","key":"2019111522000051200_B76","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/S1470-2045(10)70187-X","article-title":"Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial","volume":"11","author":"Mateos","year":"2010","journal-title":"Lancet Oncol"},{"issue":"12","key":"2019111522000051200_B77","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1182\/blood-2014-05-573733","article-title":"GEM2005 trial update comparing VMP\/VTP as induction in elderly multiple myeloma patients: do we still need alkylators?","volume":"124","author":"Mateos","year":"2014","journal-title":"Blood"},{"issue":"34","key":"2019111522000051200_B78","doi-asserted-by":"crossref","first-page":"5101","DOI":"10.1200\/JCO.2010.29.8216","article-title":"Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial","volume":"28","author":"Palumbo","year":"2010","journal-title":"J Clin Oncol"},{"issue":"3","key":"2019111522000051200_B79","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.jgo.2017.02.004","article-title":"Phase II study of dose-attenuated bortezomib, cyclophosphamide and dexamethasone (\u201cVCD-Lite\u201d) in very old or otherwise toxicity-vulnerable adults with newly diagnosed multiple myeloma","volume":"8","author":"Tuchman","year":"2017","journal-title":"J Geriatr Oncol"},{"issue":"9","key":"2019111522000051200_B80","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1182\/blood-2015-08-662627","article-title":"Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma","volume":"127","author":"Magarotto","year":"2016","journal-title":"Blood"},{"issue":"3","key":"2019111522000051200_B81","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1182\/blood-2017-07-795047","article-title":"Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma","volume":"131","author":"Facon","year":"2018","journal-title":"Blood"},{"issue":"3","key":"2019111522000051200_B82","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/bjh.14562","article-title":"Upfront lower dose lenalidomide is less toxic and does not compromise efficacy for vulnerable patients with relapsed refractory multiple myeloma: final analysis of the phase II RevLite study","volume":"177","author":"Quach","year":"2017","journal-title":"Br J Haematol"},{"issue":"19","key":"2019111522000051200_B83","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1056\/NEJMoa1112704","article-title":"Continuous lenalidomide treatment for newly diagnosed multiple myeloma","volume":"366","author":"Palumbo","year":"2012","journal-title":"N Engl J Med"},{"issue":"9","key":"2019111522000051200_B84","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1182\/blood-2015-11-679415","article-title":"Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma","volume":"127","author":"Zweegman","year":"2016","journal-title":"Blood"},{"issue":"11","key":"2019111522000051200_B85","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1182\/blood-2014-12-613927","article-title":"Melphalan, prednisone, and thalidomide vs melphalan, prednisone, and lenalidomide (ECOG E1A06) in untreated multiple myeloma","volume":"126","author":"Stewart","year":"2015","journal-title":"Blood"},{"issue":"7","key":"2019111522000051200_B86","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1200\/JCO.2013.52.0023","article-title":"Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival","volume":"32","author":"Palumbo","year":"2014","journal-title":"J Clin Oncol"},{"issue":"5","key":"2019111522000051200_B87","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1111\/bjh.14754","article-title":"Impact of concomitant dexamethasone dosing schedule on bortezomib-induced peripheral neuropathy in multiple myeloma","volume":"178","author":"Kumar","year":"2017","journal-title":"Br J Haematol"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2018\/1\/88\/1253003\/hem01812.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2018\/1\/88\/1253003\/hem01812.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,16]],"date-time":"2019-11-16T04:59:56Z","timestamp":1573880396000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2018\/1\/88\/277587\/Approach-to-the-treatment-of-the-older-unfit"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,30]]},"references-count":87,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,11,30]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2018.1.88","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,30]]}}}